Used in the development of targeted therapies for allergic and inflammatory diseases, particularly asthma. It blocks the interleukin-4 receptor alpha (IL-4Rα), inhibiting signaling pathways involved in type 2 inflammation. This suppression reduces eosinophil activation, IgE production, and mucus secretion, helping to control chronic airway inflammation. Also investigated for use in atopic dermatitis and other Th2-mediated conditions. Serves as a reference standard in bioassays and antibody development due to its well-characterized binding and neutralizing properties.